News and Press Releases
Press releases
Theralase® Release’s 3Q2024 Financial Statements
Press ReleaseTORONTO, ON / November 27, 2024 / Theralase® Technologies Inc. (“ Theralase® ” or the “ Company “) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sou...
Theralase® Closes Non-Brokered Private Placement
Press ReleaseTORONTO, ON / November 15, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/o...
Theralase® Extends Warrants
Press ReleaseTORONTO, ON / November 12, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/...
Theralase® Provides Update on Bladder Cancer Clinical Study
Press ReleaseTORONTO, ON / October 7, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or ...
Theralase® Closes Non-Brokered Private Placement and Issues Stock Options
Press ReleaseTORONTO, ON / September 24, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/o...
Theralase® Extends Warrants
Press ReleaseTORONTO, ON / September 19, 2024 / Theralase® Technologies Inc. (“Theralase” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/o...
Ruvidar™ Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus
Press ReleaseTheralase® Technologies Inc. is currently seeking partnerships / licensing opportunities in the commercial development of this latest discovery TORONTO, ON / ACCESSWIRE / September 3, 2024 / Theralase® Technologies Inc. (“Theralase®” ...
Rutherrin® Increases Efficacy of Chemotherapy for Lung Cancer
Press ReleaseV.TLT |August 28, 2024 Toronto, Ontario – Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, ra...
Theralase® Demonstrates Unique Ability to Activate Rutherrin® with Diabetes Drug
Press Release, UncategorizedToronto, Ontario –August 21 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radi...
Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement
Press Release, NMIBC, PCDs, PrivatePlacementJuly 8, 2024 - Theralase® is pleased to announce that it has successfully closed its first tranche of a Non-Brokered Private Placement ("NBPP") offering ("Offering") of units ("Units")....
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
